Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Transitioning Survival from Months to Years in Advanced NSCLC
Author
Howard (Jack) West, MD

This is a slide presentation I did last week at a local conference, describing the steady, incremental improvements in survival with advanced/metastatic non-small cell lung cancer (NSCLC) that have occurred over the past 10-15 years.  There are still many pessimists who highlight that we haven't cured metastatic lung cancer or most other advanced cancers, but I would contend that it is quite meaningful to be able to tell a patient with cancer that your treatment is quite likely to improve their survival and that, because of it, an ever-growing proportion of patients are living years with it, rather than the expectation of months that prevailed several years ago. 

This presentation highlights a couple of key developments:

1) More patients are receiving more lines of effective therapy. For patients with responsive cancer (unfortunately not everyone with advanced NSCLC), survival is improved not just with first line but also with later lines of treatment. Approaches like maintenance therapy and routine use of second line and later therapy translates to far more patients living beyond a year, sometimes well into the range of years, even independent of molecular markers.

2) A growing minority of patients are found to have a cancer that appears "driven" by a key biomarker for which we have a proven or potential target. Starting with EGFR mutations, seen in about 10% of NSCLC patients in North America, and then ALK rearrangements in another 4-5%, we've since added ROS1 and are looking at additional potentially fruitful targets like BRAF, HER2, and others.  These responses tend to be dramatic and prolonged. Even if the responses lasting years are only available to a minority of patients, we are adding to that minority year after year.

Of note, this slide deck does NOT cover immunotherapy. In part, this is because these strategies still have undefined, unproven benefit.  In addition, immunotherapy for lung cancer was the subject of a separate talk, and I did not want to encroach on that topic.

Here's the presentation. I hope you find it thought-provoking and encouraged that we're making progress, even if it can never be fast enough.

 

Next Previous link

Previous PostNext Post

Related Content

Image
Watch the Webinar Now ON Demand
Video
The Foro de Pacientes de Terapias Dirigidas de Cáncer de Pulmón presentado el 9 de agosto de 2025 has now ended.   ¡Los vídeos están disponibles BAJO DEMANDA! Las versiones completas sin editar del Foro de Pacientes de Terapias Dirigidas de Cáncer de Pulmón de agosto de 2025 ya están disponibles BAJO DEMANDA. Estos temas se editarán y se ofrecerán en forma de vídeos más cortos en las próximas semanas.  
Image
2025 Spanish Targeted Therapy in Lung Cancer Patient Forum
Article
Da click aquí para más información y para registrarte ahora
Image
Clinical Trials Storytelling 2025
Article
GRACE is pleased to introduce three amazing individuals participating in the 2024-25 GRACE Clinical Trials Experiences Storytelling Program